A therapeutic window for preventive therapy in NF1-associated optic pathway glioma

Area of Science:

• Neuro-oncology
• Developmental neuroscience
• Molecular signaling

Background:

• Pediatric low-grade gliomas (pLGGs) are the most common childhood brain tumors.
• Aberrant RAS-mediated MEK-ERK/MAPK signaling is a hallmark of pLGGs.
• The specific cell-of-origin for pLGGs in the developing brain remains largely unknown.

Purpose of the Study:

• To identify the precise cell lineage from which pLGGs originate.
• To investigate the role of the ERK-dependent signaling pathway in pLGG development.
• To develop a novel chemopreventative therapeutic strategy for pLGGs.

Main Methods:

• Utilized preclinical models to trace glioma cell lineage.
• Analyzed the MEK-ERK/MAPK signaling pathway activation in neural stem/progenitor cells.
• Evaluated a potential chemopreventative agent in a preclinical setting.

Main Results:

• Identified a specific neural stem/progenitor cell population as the origin of pLGGs.
• Confirmed the critical role of ERK-dependent signaling in tumor initiation.
• Demonstrated the efficacy of a chemopreventative strategy in preclinical models.

Conclusions:

• pLGGs arise from specific, transient neural progenitor populations during brain development.
• Targeting the RAS-MEK-ERK pathway offers a viable therapeutic avenue.
• A novel chemopreventative strategy shows promise for pLGGs.